<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359969</url>
  </required_header>
  <id_info>
    <org_study_id>C1 1209</org_study_id>
    <secondary_id>2011-000987-92</secondary_id>
    <nct_id>NCT01359969</nct_id>
  </id_info>
  <brief_title>Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients</brief_title>
  <official_title>Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2 up to and Including 13 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharming Technologies B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharming Technologies B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study is being conducted to confirm the safety, pharmacokinetic profile and
      efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema
      attacks in patients, from 2 up to and including 13 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is the assessment of safety and tolerability (adverse events, physical examination, vital signs, immunological and routine laboratory analyses et cetera)</measure>
    <time_frame>90 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity by assessing antibodies against recombinant human C1INH (IgG and IgM) anti-rhC1INH)</measure>
    <time_frame>90 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity by assessing antibodies against host related impurities (anti-HRI)</measure>
    <time_frame>90 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity by assessing IgE antibodies against rabbit epithelium</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beginning of relief</measure>
    <time_frame>24 Hours</time_frame>
    <description>Time to beginning of relief assessed by using the overall severity visual analog scale(VAS), defined as the first time point with a decrease of at least 20 mm with respect to baseline at any eligible location, with persistence at the next time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal symptoms</measure>
    <time_frame>24 Hours</time_frame>
    <description>Time to minimal symptoms assessed by using the overall severity VAS, defined as the first time point at which the overall severity VAS falls below 20 mm for each assessed location</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete resolution</measure>
    <time_frame>28 Days (diary recording)</time_frame>
    <description>Patient-recorded time at which all angioedema symptoms at all locations have resolved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters for first attack</measure>
    <time_frame>4 Hours</time_frame>
    <description>C1INH activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameters for first attack</measure>
    <time_frame>4 Hours</time_frame>
    <description>C4 levels</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>Recombinant Human C1 Inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhC1INH</intervention_name>
    <description>Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).</description>
    <arm_group_label>Recombinant Human C1 Inhibitor</arm_group_label>
    <other_name>Ruconest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  From 2 up to and including 13 years of age

          -  Clinical and laboratory confirmed diagnosis of HAE (baseline C1INH activity &lt;50% of
             normal)

          -  Signed written informed consent (parental permission) signed by the legal guardian(s)

          -  Clinical symptoms of an acute HAE attack

          -  Onset of eligible symptoms within 5 hours from the moment at which medical evaluation
             to determine eligibility has occurred

          -  Attack severity moderate or greater, as rated by the investigator

        Exclusion Criteria:

          -  A diagnosis of acquired C1INH deficiency (AAE)

          -  A medical history of allergy to rabbits or rabbit-derived products or positive
             anti-rabbit epithelium (dander) IgE test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tessa Heikamp</last_name>
    <phone>+31 71 5247 425</phone>
    <email>t.heikamp@pharming.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anurag Relan, MD</last_name>
    <phone>+31 71 5247 400</phone>
    <email>a.relan@pharming.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UIA FN Plzen ( Institute of Immunology and Allergology), Faculty Hospital Plzen</name>
      <address>
        <city>Plzen</city>
        <state>Alej Svobody 80</state>
        <zip>304 60 Plzen</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaclava Gutova, Dr.</last_name>
      <phone>420 377 103 396</phone>
      <email>gutova@fnplzen.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol, Institute of Immunology</name>
      <address>
        <city>Prague</city>
        <state>V Úvalu 84</state>
        <zip>150 06 Prague</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radana Zachova, Dr.</last_name>
      <phone>420 224 433 734</phone>
      <email>radana.zachova@fnmotol.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <state>Charitéplatz 1</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Dr. Marcus Maurer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar, Technical University Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Dr. Murat Bas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heim Pál Gyermekkórház, II. számú Gyermek Belgyógyászati Osztály</name>
      <address>
        <city>Budapest</city>
        <state>Madarász Utca 22-24</state>
        <zip>1131</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ferenc Fekete, Dr.</last_name>
      <phone>+36 70 365 8538</phone>
      <email>fejesj01@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ferenc Fekete, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henriette Farkas, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bnei Zion Hospital</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Aharon Kessel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Avner Reshef</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Souraski Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Dr. Shmuel Kivity</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Luigi Sacco</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Dr. Marco Cicardi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria S. Giovanni di Dio e Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Dr. Massimo Triggiani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic Of Dermatology Skopje</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. dr. Vesna Grivcheva Panovska, Prof. dr.</last_name>
      <phone>0038 92 31 22 265</phone>
      <email>vesna_grivcheva_panovska@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Hospital</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Maria Klimaszewska-Rembiasz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Hospital</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. Andrzej Emeryk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mures County Clinical Hospital</name>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Prof. dr. Dumitru Moldovan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika detí a dorastu, Univerzitna nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <state>Kollárova 2</state>
        <zip>036 59 Martin</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milos Jesenak, Prof. Dr.</last_name>
      <phone>421 434 203 254</phone>
      <email>jesenak@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary Angioedema</keyword>
  <keyword>HAE</keyword>
  <keyword>Angioedema</keyword>
  <keyword>Recombinant C1 Inhibitor</keyword>
  <keyword>rhC1INH</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 3, 2018</submitted>
    <returned>May 3, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

